CVM vs. CRBU, GNFT, IPSC, MGX, ZURA, IPHA, ELEV, IVVD, CHRS, and GLUE
Should you be buying CEL-SCI stock or one of its competitors? The main competitors of CEL-SCI include Caribou Biosciences (CRBU), Genfit (GNFT), Century Therapeutics (IPSC), Metagenomi (MGX), Zura Bio (ZURA), Innate Pharma (IPHA), Elevation Oncology (ELEV), Invivyd (IVVD), Coherus BioSciences (CHRS), and Monte Rosa Therapeutics (GLUE). These companies are all part of the "biological products, except diagnostic" industry.
CEL-SCI (NYSE:CVM) and Caribou Biosciences (NASDAQ:CRBU) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, community ranking, earnings, media sentiment, dividends, risk and analyst recommendations.
CEL-SCI has higher earnings, but lower revenue than Caribou Biosciences. CEL-SCI is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.
CEL-SCI has a net margin of 0.00% compared to Caribou Biosciences' net margin of -345.05%. Caribou Biosciences' return on equity of -33.42% beat CEL-SCI's return on equity.
Caribou Biosciences has a consensus target price of $15.25, indicating a potential upside of 682.05%. Given Caribou Biosciences' higher probable upside, analysts plainly believe Caribou Biosciences is more favorable than CEL-SCI.
Caribou Biosciences received 18 more outperform votes than CEL-SCI when rated by MarketBeat users. Likewise, 52.94% of users gave Caribou Biosciences an outperform vote while only 0.00% of users gave CEL-SCI an outperform vote.
12.1% of CEL-SCI shares are owned by institutional investors. Comparatively, 77.5% of Caribou Biosciences shares are owned by institutional investors. 16.2% of CEL-SCI shares are owned by company insiders. Comparatively, 9.5% of Caribou Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
In the previous week, Caribou Biosciences had 6 more articles in the media than CEL-SCI. MarketBeat recorded 7 mentions for Caribou Biosciences and 1 mentions for CEL-SCI. CEL-SCI's average media sentiment score of 0.00 beat Caribou Biosciences' score of -0.68 indicating that CEL-SCI is being referred to more favorably in the media.
CEL-SCI has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500. Comparatively, Caribou Biosciences has a beta of 2.43, meaning that its share price is 143% more volatile than the S&P 500.
Summary
Caribou Biosciences beats CEL-SCI on 11 of the 16 factors compared between the two stocks.
Get CEL-SCI News Delivered to You Automatically
Sign up to receive the latest news and ratings for CVM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CVM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
